Back to Search
Start Over
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial
- Source :
- The Lancet Respiratory Medicine; February 2022, Vol. 10 Issue: 2 p158-166, 9p
- Publication Year :
- 2022
-
Abstract
- Acute respiratory distress syndrome (ARDS) is a major complication of COVID-19 and is associated with high mortality and morbidity. We aimed to assess whether intravenous immunoglobulins (IVIG) could improve outcomes by reducing inflammation-mediated lung injury.
Details
- Language :
- English
- ISSN :
- 22132600 and 22132619
- Volume :
- 10
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- The Lancet Respiratory Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs58251963
- Full Text :
- https://doi.org/10.1016/S2213-2600(21)00440-9